Table 3.
Cytotoxic activities of compounds 1–6 and their mixtures with cholesterol. Values are indicated as mean ± standard deviation.
| Compound | Inhibiting Concentration, (IC50), µM | |||||||
|---|---|---|---|---|---|---|---|---|
| HEK 293 | HT-29 | RPMI-7951 | MDA-MB-231 | |||||
| a | b | a | b | a | b | a | b | |
| 1 | >40 | n.d. | >40 | n.d. | >40 | n.d. | >40 | n.d. |
| 2 | 28.6 ± 2.1 | >40 | 26.2 ± 2.5 | >40 | 20.4 ± 1.6 | >40 | 21.5 ± 0.5 | >40 |
| 3 | 6.7 ± 0.2 | 24.2 ± 4.0 | 6.2 ± 0.3 | 19.4 ± 3.3 | 23.7 ± 0.4 | >40 | 6.4 ± 0.4 | 20.0 ± 4.7 |
| 4 | 5.5 ± 0.3 | 17.3 ± 0.8 | 5.3 ± 0.2 | 14.3 ± 3.0 | 5.8 ± 1.2 | 16.4 ± 3.1 | 3.6 ± 0.2 | 12.8 ± 0.7 |
| 5 | 7.9 ± 0.9 | 19.5 ± 1.2 | 5.5 ± 0.6 | 15.9 ± 0.26 | 5.9 ± 0.9 | 17.0 ± 2.8 | 4.4 ± 0.09 | 12.9 ± 2.5 |
| 6 | 6.3 ± 0.6 | 13.2 ± 0.5 | 7.8 ± 0.7 | 10.9 ± 0.05 | 5.8 ± 2.6 | 11.4 ± 0.8 | 5.5 ± 0.1 | 10.5 ± 1.8 |
IC50, the concentration of compounds that caused a 50% reduction in cell viability of tested normal and cancer cells. a IC50 of individual compounds 1–6 for 24 h. b IC50 of 1–6 combined with cholesterol for 24 h. n.d.—not determined.